Biosimilar Antibodies

Opicinumab (BIIB033) is a monoclonal antibody specifically targeting LINGO-1, a protein implicated in the inhibition of axonal regeneration and myelination. This antibody is under investigation for its potential therapeutic applications in treating acute optic neuritis as well as relapsing forms of multiple sclerosis, aiming to enhance neuronal repair and improve neurological function.

Senlizumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to bind to TNFSF2/TNFα. This antibody is constructed from human IgG4SP heavy chains and human kappa light chains, exhibiting a predicted molecular weight of approximately 146.9 kDa. For experimental controls, Human IgG4 kappa, Isotype Control is recommended.

The Anti-Mesothelin Antibody (YP218) is a chimeric rabbit IgG that specifically targets human Mesothelin. This antibody is designed for precision in detecting and binding to the Mesothelin protein, which is prominently expressed in various forms of cancer, including mesothelioma and ovarian carcinoma. Suitable for a range of research applications, this antibody provides a valuable tool for the study of Mesothelin's role in cancer pathogenesis and potential therapeutic interventions.

Dilpacimab (ABT165) is a dual-variable domain immunoglobulin engineered for high potency, simultaneously targeting the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways. This bifunctional antibody is designed to inhibit two critical signaling pathways involved in angiogenesis and tumor growth, making it a valuable tool for cancer research. Dilpacimab is suitable for use in various experimental settings to explore the role of these pathways in oncogenesis and potential therapeutic interventions.

Gefurulimab (ALXN-1720) is a bispecific human-derived antibody designed to target complement component C5 and albumin. This antibody binds specifically to C5, effectively inhibiting its activation. The dual targeting mechanism allows for enhanced circulation time and improved pharmacokinetic profile, making it a valuable tool for research in immune response and complement system disorders.

Roledumab (LFB-R593) is a human IgG1-κ monoclonal antibody that specifically targets the RHD antigen, also known as CD240D. This antibody is produced in YB2/0 rat hybridoma cells, ensuring high specificity and affinity for its antigen. Roledumab is utilized primarily in research focused on RhD antigen expression and its immunological implications, making it a valuable tool in studies related to blood typing, Rh disease, and other hematological disorders.

Mipletamig is a chimeric antibody comprising both human and humanized elements, specifically designed to target CD3E. Its structure includes a [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 format, integrating single-chain variable fragments (scFv) linked to the constant regions of human immunoglobulin G1 heavy chains (CH2-CH3). This antibody is engineered for high specificity and affinity toward CD3E, making it an invaluable tool in immunological research and therapeutic development.

The Anti-ACVR2A Antibody (Ab-14E1) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the ACVR2A receptor, which plays a crucial role in the TGF-beta signaling pathway, influencing cellular processes such as proliferation and differentiation. This antibody is comprised of an IgG1 heavy chain and a human kappa (huκ) light chain, and has a molecular weight of approximately 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as an appropriate isotype control for this antibody. This product is essential for research in cellular signaling and regulatory mechanisms, particularly in the context of developmental biology and cancer research.

The Anti-ADAM9 Antibody (MGA021), also known as IMGC-936 antibody, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the ADAM9 enzyme, a member of the disintegrin and metalloproteinase domain-containing protein family, which plays a crucial role in cellular signaling, adhesion, and migration. The Anti-ADAM9 Antibody (MGA021) is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, and has a predicted molecular weight of 147.62 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as a suitable isotype control for this antibody. This product is essential for researchers focusing on cancer biology, tissue remodeling, and inflammatory processes where ADAM9 is implicated.

Priliximab (CEN 000029) is a humanized monoclonal antibody targeting CD4, a surface glycoprotein predominantly expressed on T cells. By binding to CD4, Priliximab induces a significant and sustained decrease in circulating CD4+ T cell populations. This antibody is primarily utilized in the investigation of immune response mechanisms in conditions such as rheumatoid arthritis (RA), providing valuable insights into therapeutic strategies aimed at modulating T cell activity.

Belantamab (GSK2857916) is a humanized IgG1 monoclonal antibody targeting BCMA (B-cell maturation antigen), also known as TNFRSF17. This antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, forming the antibody-drug conjugate (ADC) Belantamab mafodotin. Upon binding to BCMA expressed on the surface of tumor cells, Belantamab mafodotin is internalized through receptor-mediated endocytosis. Inside the cell, the conjugate releases MMAF, which inhibits tubulin polymerization, leading to cell cycle arrest and subsequent induction of apoptosis in the tumor cells. This mechanism positions Belantamab mafodotin as a potent therapeutic agent for the investigation of multiple myeloma, particularly in cases of relapsed or refractory disease.

Obrindatamab is a humanized bispecific antibody that targets both B7-H3 and CD3. By binding to these molecules, Obrindatamab facilitates the redirection of cytotoxic T-lymphocyte (CTL) activity towards cancer cells expressing B7-H3. This antibody is utilized primarily in cancer research to study immune-mediated tumor cell eradication.

Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody engineered to selectively bind to and inhibit the glucagon receptor (GCGR). This antibody demonstrates a high affinity for GCGR with a dissociation constant (K_D) of 0.1 nM, indicating potent binding capability. Crotedumab is primarily utilized in diabetes research, where modulation of the glucagon receptor is implicated in glucose homeostasis and diabetic pathology.

Ubamatamab (REGN4018) is a humanized bispecific antibody that specifically targets Mucin 16 (MUC16) and CD3. This antibody has demonstrated potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Ubamatamab engages both tumor cells expressing MUC16 and T-cells via CD3, facilitating an immune response against the tumor cells. This dual targeting mechanism is critical for its application in studies focused on ovarian and other MUC16-positive cancers.

Obrixtamig is a chimeric human antibody designed to target CD3E and HEK. It is comprised of both kappa (κ) and lambda (λ) light chains and includes the human G1 heavy chain constant regions (CH2-CH3). This dual specificity and structural composition enhance its applicability in various immunological research settings, focusing on the modulation of T-cell activity and potential cellular engineering studies.

Pacibekitug is a human monoclonal antibody of the IgG2κ subclass that specifically targets interleukin-6 (IL-6). For experimental control purposes, it is recommended to use Human IgG2 kappa as an isotype control. This antibody is suitable for a variety of research applications focusing on the biological role and therapeutic targeting of IL-6.

Tisotumab is a recombinant human IgG1 monoclonal antibody and antibody-drug conjugate (ADC) specifically designed to target Tissue Factor (TF), a cell surface glycoprotein frequently overexpressed in various solid tumors. This antibody's specificity for TF makes it a valuable tool for the study of solid tumor pathophysiology and potential therapeutic interventions. Tisotumab's role in targeting and binding to TF allows for precise delivery of cytotoxic agents in the context of cancer research, making it an essential component for studies focused on oncology and tumor biology.

Erzotabart is a monoclonal antibody of the IgG1-kappa subtype that targets CD38 (also known as ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, or cADPR hydrolase 1) in Homo sapiens. This antibody exhibits antineoplastic activity, making it a valuable tool for research in cancer therapy.

Enibarcimab is a humanized murine monoclonal immunoglobulin G1 (IgG1) antibody designed for potential application in the research of acute heart failure, COVID-19 infections, and septic shock. This antibody targets specific antigens associated with these conditions, offering a valuable tool for detailed study and potential therapeutic development.

The Anti-ABCB5 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the ATP-binding cassette sub-family B member 5 (ABCB5). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain and exhibits a predicted molecular weight of 145 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research applications focused on the function and expression of ABCB5 in various biological systems.

VB1-050 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the SLC2A8 protein. This antibody is structured with human IgG1 heavy chains and human kappa light chains, and exhibits a predicted molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for use in various biochemical assays and research applications focusing on the role and function of the SLC2A8 protein.

BNC101 is a human-specific monoclonal antibody that targets GPCR-LGR5, also known as GPR49. This antibody is designed for therapeutic use in the management of metastatic colorectal cancer (CRC), leveraging its specificity to bind to the LGR5 receptor, which plays a critical role in cancer stem cell biology and tumor growth. BNC101 holds potential for advancing CRC treatment by selectively targeting and modulating LGR5-expressing cells.

Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody specifically designed to target TNFSF15/TL1A. It is produced in CHOK1SV cells, which endogenously express glutamine synthetase (GS), optimizing the antibody's expression and stability. This antibody is primarily utilized in research focused on understanding and potentially treating Crohn's Disease (CD), offering significant value for disease model studies and therapeutic development.

Samrotamab is a chimeric humanized antibody of the IgG1-κ isotype, specifically designed to target the leucine-rich repeat-containing 15 (LRRC15) protein. This monoclonal antibody binds selectively to LRRC15, a protein expressed in various tumor types, making it a valuable tool for cancer research and therapeutic development.

Tezepelumab is a human monoclonal antibody (IgG2λ) designed to bind with high specificity to thymic stromal lymphopoietin (TSLP). By attaching to TSLP, Tezepelumab prevents its interaction with the heterodimeric receptor complex, effectively inhibiting the TSLP-mediated signaling pathway. This antibody is primarily utilized in research focused on severe, uncontrolled asthma, providing a valuable tool for understanding the underlying mechanisms of this condition and exploring potential therapeutic strategies.

Sarilumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, specifically targeting the alpha subunit of the human interleukin-6 receptor (IL-6Rα). As an antagonist to IL-6, Sarilumab binds with high affinity to IL-6Rα, effectively inhibiting both cis and trans signaling pathways mediated by IL-6. This inhibition plays a crucial role in modulating inflammatory responses, making Sarilumab a valuable tool for investigating the pathophysiology and potential therapeutic interventions for rheumatoid arthritis.

Tifcemalimab (JS004) is a humanized monoclonal antibody that targets BTLA (B and T lymphocyte attenuator), a key regulator in the immune checkpoint pathway. By binding specifically to BTLA, Tifcemalimab effectively inhibits the interaction between BTLA and its ligand HVEM, thereby blocking the BTLA-mediated inhibitory signaling pathway. This antibody is primarily utilized in cancer research to study the modulation of immune responses against tumor cells.

Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody designed for high specificity and potency in binding to calcitonin gene-related peptide (CGRP). CGRP, a 37-amino acid neuropeptide, plays a critical role in the central and peripheral mechanisms underlying migraine pathophysiology. This antibody is particularly relevant for research focused on chronic migraine, providing a valuable tool for elucidating the biological pathways involved in this condition.

The Anti-TIM-1/KIM-1/CD365 Antibody (clone 2.70.2) is a monoclonal antibody that specifically targets the TIM-1/KIM-1/CD365 antigen. This antibody is designed for the precise detection and characterization of the T cell immunoglobulin and mucin-domain containing-1 (TIM-1), also known as kidney injury molecule-1 (KIM-1) and CD365. It is widely utilized in research focused on immunology, renal injury, and cancer, due to its role in mediating cellular immune responses and its upregulation in damaged kidney cells. This product is suitable for a variety of applications including flow cytometry, Western blotting, and immunohistochemistry.

Taplitumomab is a monoclonal antibody targeting CD19, a protein primarily expressed on the surface of B cells. This specificity makes Taplitumomab a valuable tool in cancer research, particularly for studying B-cell malignancies. The conjugated form, Taplitumomab paptox, incorporates a toxin for targeted cytotoxic activity, enhancing its utility in investigating therapeutic approaches for cancer treatment.

Duligotuzumab, also known as MEHD-7945A and RG 7597, is a humanized IgG-κ monoclonal antibody designed for high specificity towards Her3 (ErbB3). This antibody has been engineered for research applications focusing on the ErbB3 signaling pathways, which are critical in the study of cellular growth, differentiation, and survival mechanisms. Duligotuzumab is utilized primarily in cancer research, where ErbB3 plays a significant role in tumor growth and progression.

The Anti-VEGFR2/KDR/CD309 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), also known as Kinase Insert Domain Receptor (KDR) or CD309. This antibody comprises a murine IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For accurate experimental controls, it is recommended to use the Human IgG1 kappa, Isotype Control, which is designed to match the isotype of this antibody. This product is essential for research in angiogenesis, vascular biology, and oncology, providing a valuable tool for both therapeutic and diagnostic development.

Tocilizumab, a humanized monoclonal antibody, targets and neutralizes the interleukin-6 receptor (IL-6R). By blocking the interaction of IL-6 with IL-6R, Tocilizumab effectively inhibits both classical and trans-signaling pathways. This antibody is primarily utilized in the therapeutic management of rheumatoid arthritis, leveraging its ability to modulate inflammatory responses. Additionally, Tocilizumab has demonstrated significant efficacy in research focused on severe cases of COVID-19, highlighting its potential in addressing cytokine release syndrome and related complications. This makes it a valuable tool for both clinical and research applications in immune-mediated inflammatory disorders.

The Anti-NOTCH1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the NOTCH1 protein. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. This product is ideal for use in various immunological assays to study the role of NOTCH1 in cellular differentiation, proliferation, and apoptotic processes.

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody designed to specifically target the human B7-H3 protein, which is part of the B7 family of immune regulators. This antibody has been engineered for high specificity and affinity in recognizing its antigen, making it suitable for research focused on immune regulation and potential therapeutic applications.

Tanruprubart is a monoclonal antibody engineered to target human complement C1q. This antibody binds specifically to C1q, effectively inhibiting the initiation of the classical complement activation pathway. By blocking this pathway, Tanruprubart demonstrates significant immunosuppressive properties, making it an invaluable tool for research into autoimmune and inflammation-related diseases. Its precise targeting offers potential for detailed studies on the role of complement activation in pathological conditions.

The Anti-LY75/CD205 Antibody (MEN1309) is a recombinant human monoclonal antibody expressed in Chinese hamster ovary (CHO) cells. This antibody specifically targets LY75/CD205, also known as DEC-205, a receptor involved in antigen uptake and presentation in immune cells. The antibody is composed of a human IgG1 type heavy chain and a human kappa light chain, with a predicted molecular weight of 145.36 kDa. For research purposes, a Human IgG1 kappa Isotype Control is recommended for use in assay validation to differentiate specific from non-specific binding.

Ociperlimab is a humanized IgG1 monoclonal antibody targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT). It exhibits high-affinity binding to the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. By inhibiting the interaction between TIGIT and its ligands, poliovirus receptor (PVR) and PVR-like 2 (PVR-L2), Ociperlimab serves as a potent tool in the modulation of immune responses. This antibody is particularly useful in the research of cancer immunotherapy, facilitating the study of TIGIT as an immune checkpoint in various oncological models.

Peresolimab is a humanized IgG1-κ monoclonal antibody designed to specifically target PD-1 (Programmed Death-1). This antibody functions by potentially stimulating physiological immune inhibitory pathways, thereby aiming to restore immune homeostasis. Peresolimab is utilized primarily in research focused on the modulation of immune checkpoint pathways, which are critical for understanding and manipulating immune responses in various disease states, including oncology and autoimmune disorders.

Vedolizumab, a humanized IgG1 monoclonal antibody, selectively binds to the α4β7 integrin. This targeted mechanism is pivotal in the management of immune responses in the gastrointestinal tract, making it an effective therapeutic option for ulcerative colitis and Crohn's disease.

Alsevalimab is a human monoclonal antibody specifically designed to target and bind to the B7-H4 protein. This interaction plays a critical role in modulating immune responses, making Alsevalimab a valuable tool for research into immunological pathways and potential therapeutic applications in diseases where B7-H4 is implicated.

Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody specifically designed to target TNFSF15, also known as TL1A. This antibody is utilized in the investigation of various inflammatory and fibrotic diseases, including Crohn's Disease and ulcerative colitis. Tulisokibart's specificity for TL1A makes it a valuable tool in the study of the pathogenesis and potential therapeutic interventions for these conditions.

Atezolizumab (MPDL3280A) is a humanized monoclonal IgG1 antibody selectively targeting programmed death ligand 1 (PD-L1). This antibody is utilized extensively in oncological research to investigate the modulation of the immune system's response against cancer cells. Atezolizumab's specificity for PD-L1 aids in the study of immune checkpoint pathways, potentially leading to new therapeutic strategies in cancer treatment.

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to selectively target the TNF-like weak inducer of apoptosis receptor (TWEAK receptor, TweakR). This receptor is naturally engaged by its ligand TWEAK (TNFRSF12A), which activates various cellular responses. By binding to TweakR, Enavatuzumab inhibits tumor proliferation through direct receptor signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC). This antibody has demonstrated efficacy in recruiting and activating myeloid effector cells to eradicate tumor cells. Enavatuzumab has shown to inhibit the growth of a range of human TweakR-positive cancer cell lines and xenografts both in vitro and in vivo, marking it as a potent therapeutic agent in cancer research and treatment.

Anifrolumab is a human monoclonal antibody that functions as a type I interferon (IFN) receptor antagonist. By blocking the activity of type I interferons, Anifrolumab serves as a critical tool in the study of systemic lupus erythematosus (SLE). This antibody provides a valuable means for researchers to explore the role of type I IFN in the pathogenesis and potential therapeutic targeting of SLE.

Traxivitug is a human IgG1 λ2 monoclonal antibody designed to target and neutralize BK virus (BKV). For accurate experimental control, it is recommended to use Human IgG1 λ2, Isotype Control.

Imdevimab (REGN10987) is a human monoclonal antibody designed specifically to target the SARS-CoV-2 virus responsible for COVID-19. Although it demonstrates limited efficacy against emerging COVID-19 variants, when used in conjunction with Casirivimab, Imdevimab has been shown to significantly reduce viral load and enhance disease outcomes. This combination therapy is pivotal for managing viral replication and improving patient response during treatment.